Multiple immune and hematopoietic cell populations and signaling pathways

The term "Multiple immune and hematopoietic cell populations and signaling pathways" refers to the integrated network of specialized cells and intracellular biochemical cascades responsible for immunity and blood cell production (Kaushansky, 2006, NEJM). This system includes various cell types such as T-lymphocytes, B-lymphocytes, neutrophils, and hematopoietic stem cells, which communicate through complex pathways like JAK/STAT, NF-kappaB, and PI3K/AKT/mTOR (Abbas et al., 2021, Cellular and Molecular Immunology). While these pathways and cells are the focus of numerous therapeutic interventions, the term itself represents a broad physiological category rather than a discrete molecular target (Swinney & Anthony, 2011, Nature Reviews Drug Discovery). In drug development, specific proteins within these pathways are targeted to treat a wide range of conditions, including autoimmune disorders, inflammatory diseases, and hematologic malignancies. Therapeutic strategies often involve modulating specific nodes within these networks to restore immune homeostasis or eliminate malignant cell populations. Because it encompasses a vast array of distinct biological entities, it does not meet the criteria for a single, specific therapeutic target in pharmacological databases like IUPHAR/BPS Guide to Pharmacology.

Other names

Immune and hematopoietic systemsImmune signaling networksHematopoietic signaling pathways

Not applicable; this term describes a broad biological system rather than a specific molecular mechanism of action.